Quick Answer
ABVC BIOPHARMA, INC. reported Stockholders Equity of $11.11 million for the year ending 2025.
- ABVC BIOPHARMA, INC. showed an increase of +806.2% in Stockholders Equity from 2024 to 2025.
- This data is from ABVC BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2010 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: $29.5 thousand | Q1 2015: $28.7 thousand | Q2 2015: $29.9 thousand | Q4 2015: $64.9 thousand | Q2 2016: $1.53 million | Q1 2017: -$922.8 thousand | Q2 2017: -$1.05 million | Q1 2018: -$1.93 million | Q2 2018: -$2.24 million | Q3 2018: -$2.45 million | Q1 2019: -$5.76 million | Q2 2019: -$3.32 million | Q3 2019: $665.9 thousand | Q1 2020: -$1.14 million | Q2 2020: -$1.07 million | Q3 2020: -$536.4 thousand | Q1 2021: $2.57 million | Q2 2021: $1.44 million | Q3 2021: $8.59 million | Q1 2022: $7.43 million | Q2 2022: $9.33 million | Q3 2022: $5.92 million | Q1 2023: $1.67 million | Q2 2023: -$379.3 thousand | Q3 2023: $9.10 million | Q1 2024: $1.70 million | Q2 2024: $1.79 million | Q3 2024: $1.64 million | Q1 2025: $5.40 million | Q2 2025: $7.01 million | Q3 2025: $12.06 million.
- Over the full 19 years of available data (2010 to 2025), ABVC BIOPHARMA, INC.'s Stockholders Equity has grown by 471.2%.
- Historical annual values: Fiscal year 2025: $11.11 million | Fiscal year 2024: $1.23 million | Fiscal year 2023: $1.55 million | Fiscal year 2022: $3.10 million | Fiscal year 2021: $8.84 million | Fiscal year 2020: $3.44 million | Fiscal year 2019: -$151.0 thousand | Fiscal year 2018: -$5.66 million | Fiscal year 2017: -$1.76 million | Fiscal year 2017: -$1.39 million | Fiscal year 2016: -$6.52 million | Fiscal year 2016: -$6.38 million | Fiscal year 2015: $633.4 thousand | Fiscal year 2015: $897.0 thousand | Fiscal year 2014: $31.4 thousand | Fiscal year 2013: -$1.88 million | Fiscal year 2012: -$1.64 million | Fiscal year 2011: -$1.46 million | Fiscal year 2010: -$2.99 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: